A newly launched phase 3 clinical trial will investigate whether moxidectin, a drug currently used to treat parasites in animals, can speed the elimination of onchocerciasis, or river blindness, one of the leading causes of blindness across Africa (http://apps.who.int/tdr/news-events/news/pdf/moxidectin-press-release.pdf). The Special Program for Research and Training in Tropical Diseases, which is administered by the World Health Organization, will conduct the trial with African investigators and institutions and enroll 1500 individuals at 4 sites in Ghana, Liberia, and the Democratic Republic of the Congo.
Stephenson J. River Blindness Trial. JAMA. 2009;302(7):732. doi:10.1001/jama.2009.1158